Novel 2-substituted 4,5-diaryl imidazoles in which:
i) the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, or
ii) the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, amino or hydrazino, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members,
are provided, in particular compounds of Formula I
wherein R1, R2, R3 and R4 are as defined, in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form, which have p38 MAP kinase (Mitogen Activated Protein Kinase) inhibiting activity. The compounds are used as pharmaceuticals for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.
新颖的 2-取代 4,5-二基
咪唑,其中:
i) 位于 1 位的氮原子被含有三烷基
硅烷基的取代基取代,或
ii) 2 位上的取代基为芳烷基、芳磺酰基、芳
硫基、芳
硒基、芳
碲基、环烷基、 环烯基、烷基环烷基、烷基环烯基、
氨基或
肼基、或单环或双环 N-杂环烷基,其中含 N 的环有六个环成员、
特别是式 I 的化合物
其中 R1、R2、R3 和 R4 如所定义,以游离态或药学上可接受的酸加成盐或生理上可裂解的酯形式存在,具有 p38
MAP 激酶(丝裂原活化蛋白激酶)抑制活性。这些化合物可作为药物用于治疗 TNFα 和 IL-1 介导的疾病,如类风湿性关节炎和骨代谢疾病,如骨质疏松症。